Skip to content

Study · Randomized controlled trial · n = 20 · 2017

11 results

Once-weekly dulaglutide 1.5 mg restores insulin secretion in response to intravenous glucose infusion.

de la Peña A, Loghin C, Cui X, Zhang X, Kapitza C, Kelly RP

Diabetes, obesity & metabolism17 Feb 2017Cited by 2 (Europe PMC)

PMID27976833 (opens in a new tab)DOI10.1111/dom.12847 (opens in a new tab)PepBankPUB-27976833
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In subjects with T2DM, dulaglutide increased first-phase insulin AUC 7.92-fold versus placebo.

    In plain wordsIn people with T2DM, dulaglutide increased first-phase insulin exposure versus placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseFirst-phase insulin AUC in T2DM
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg · subcutaneousAs given in this study (human).

    Measurements

    Insulin AUC ratio
    7.92 fold
    T2DM versus placebo

    Source sentences

    Summary
    In 20 subjects with T2DM, dulaglutide increased mean insulin AUC0-10 by 7.92-fold and Cmax0-10 by 5.40-fold vs placebo, and mean AUC10-180 and Cmax10-180 by 2.44- and 3.78- fold, respectively.
    1 context sentence
    Summary · context
    In this randomized, double-blind, placebo-controlled, 2-period crossover study, subjects received a single subcutaneous injection of dulaglutide 1.5 mg or placebo on day 1 of each period.
  2. 02HumanRandomized controlled trialMechanism

    In subjects with T2DM, dulaglutide increased first-phase maximum insulin concentration 5.40-fold versus placebo.

    In plain wordsIn people with T2DM, dulaglutide increased the first-phase insulin peak versus placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseFirst-phase insulin maximum in T2DM
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg · subcutaneousAs given in this study (human).

    Measurements

    Insulin Cmax0-10 ratio
    5.4 fold
    T2DM versus placebo

    Source sentences

    Summary
    In 20 subjects with T2DM, dulaglutide increased mean insulin AUC0-10 by 7.92-fold and Cmax0-10 by 5.40-fold vs placebo, and mean AUC10-180 and Cmax10-180 by 2.44- and 3.78- fold, respectively.
    1 context sentence
    Summary · context
    In this randomized, double-blind, placebo-controlled, 2-period crossover study, subjects received a single subcutaneous injection of dulaglutide 1.5 mg or placebo on day 1 of each period.
  3. 03HumanRandomized controlled trialMechanism

    In subjects with T2DM, dulaglutide increased second-phase insulin AUC 2.44-fold versus placebo.

    In plain wordsIn people with T2DM, dulaglutide increased second-phase insulin exposure versus placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseSecond-phase insulin AUC in T2DM
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg · subcutaneousAs given in this study (human).

    Measurements

    Insulin AUC10-180 ratio
    2.44 fold
    T2DM versus placebo

    Source sentences

    Summary
    In 20 subjects with T2DM, dulaglutide increased mean insulin AUC0-10 by 7.92-fold and Cmax0-10 by 5.40-fold vs placebo, and mean AUC10-180 and Cmax10-180 by 2.44- and 3.78- fold, respectively.
    1 context sentence
    Summary · context
    In this randomized, double-blind, placebo-controlled, 2-period crossover study, subjects received a single subcutaneous injection of dulaglutide 1.5 mg or placebo on day 1 of each period.
  4. 04HumanRandomized controlled trialMechanism

    In subjects with T2DM, dulaglutide increased second-phase maximum insulin concentration 3.78-fold versus placebo.

    In plain wordsIn people with T2DM, dulaglutide increased the second-phase insulin peak versus placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseSecond-phase insulin maximum in T2DM
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg · subcutaneousAs given in this study (human).

    Measurements

    Insulin Cmax10-180 ratio
    3.78 fold
    T2DM versus placebo

    Source sentences

    Summary
    In 20 subjects with T2DM, dulaglutide increased mean insulin AUC0-10 by 7.92-fold and Cmax0-10 by 5.40-fold vs placebo, and mean AUC10-180 and Cmax10-180 by 2.44- and 3.78- fold, respectively.
    1 context sentence
    Summary · context
    In this randomized, double-blind, placebo-controlled, 2-period crossover study, subjects received a single subcutaneous injection of dulaglutide 1.5 mg or placebo on day 1 of each period.
  5. 05HumanRandomized controlled trialMechanism

    In healthy subjects, dulaglutide increased first-phase insulin AUC 3.09-fold versus placebo.

    In plain wordsIn healthy people, dulaglutide increased first-phase insulin exposure versus placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseFirst-phase insulin AUC in healthy subjects
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg · subcutaneousAs given in this study (human).

    Measurements

    Insulin AUC0-10 ratio
    3.09 fold
    healthy subjects versus placebo

    Source sentences

    Summary
    In 10 healthy subjects, dulaglutide increased the mean insulin AUC0-10 by 3.09-fold and Cmax0-10 by 2.96-fold vs placebo, and mean AUC10-180 and Cmax10-180 by 2.04- and 4.15-fold, respectively.
    1 context sentence
    Summary · context
    In this randomized, double-blind, placebo-controlled, 2-period crossover study, subjects received a single subcutaneous injection of dulaglutide 1.5 mg or placebo on day 1 of each period.
  6. 06HumanRandomized controlled trialMechanism

    In healthy subjects, dulaglutide increased first-phase maximum insulin concentration 2.96-fold versus placebo.

    In plain wordsIn healthy people, dulaglutide increased the first-phase insulin peak versus placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseFirst-phase insulin maximum in healthy subjects
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg · subcutaneousAs given in this study (human).

    Measurements

    Insulin Cmax0-10 ratio
    2.96 fold
    healthy subjects versus placebo

    Source sentences

    Summary
    In 10 healthy subjects, dulaglutide increased the mean insulin AUC0-10 by 3.09-fold and Cmax0-10 by 2.96-fold vs placebo, and mean AUC10-180 and Cmax10-180 by 2.04- and 4.15-fold, respectively.
    1 context sentence
    Summary · context
    In this randomized, double-blind, placebo-controlled, 2-period crossover study, subjects received a single subcutaneous injection of dulaglutide 1.5 mg or placebo on day 1 of each period.
  7. 07HumanRandomized controlled trialMechanism

    In healthy subjects, dulaglutide increased second-phase insulin AUC 2.04-fold versus placebo.

    In plain wordsIn healthy people, dulaglutide increased second-phase insulin exposure versus placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseSecond-phase insulin AUC in healthy subjects
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg · subcutaneousAs given in this study (human).

    Measurements

    Insulin AUC10-180 ratio
    2.04 fold
    healthy subjects versus placebo

    Source sentences

    Summary
    In 10 healthy subjects, dulaglutide increased the mean insulin AUC0-10 by 3.09-fold and Cmax0-10 by 2.96-fold vs placebo, and mean AUC10-180 and Cmax10-180 by 2.04- and 4.15-fold, respectively.
    1 context sentence
    Summary · context
    In this randomized, double-blind, placebo-controlled, 2-period crossover study, subjects received a single subcutaneous injection of dulaglutide 1.5 mg or placebo on day 1 of each period.
  8. 08HumanRandomized controlled trialMechanism

    In healthy subjects, dulaglutide increased second-phase maximum insulin concentration 4.15-fold versus placebo.

    In plain wordsIn healthy people, dulaglutide increased the second-phase insulin peak versus placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseSecond-phase insulin maximum in healthy subjects
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg · subcutaneousAs given in this study (human).

    Measurements

    Insulin Cmax10-180 ratio
    4.15 fold
    healthy subjects versus placebo

    Source sentences

    Summary
    In 10 healthy subjects, dulaglutide increased the mean insulin AUC0-10 by 3.09-fold and Cmax0-10 by 2.96-fold vs placebo, and mean AUC10-180 and Cmax10-180 by 2.04- and 4.15-fold, respectively.
    1 context sentence
    Summary · context
    In this randomized, double-blind, placebo-controlled, 2-period crossover study, subjects received a single subcutaneous injection of dulaglutide 1.5 mg or placebo on day 1 of each period.
  9. 09HumanRandomized controlled trialMechanism

    In subjects with T2DM and healthy subjects, corresponding C-peptide values increased with dulaglutide versus placebo.

    In plain wordsDulaglutide increased corresponding C-peptide responses versus placebo in people with T2DM and healthy people.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseC-peptide response
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The corresponding C-peptide values also increased.
    3 context sentences
    Summary · context
    In 20 subjects with T2DM, dulaglutide increased mean insulin AUC0-10 by 7.92-fold and Cmax0-10 by 5.40-fold vs placebo, and mean AUC10-180 and Cmax10-180 by 2.44- and 3.78- fold, respectively.
    Summary · context
    In 10 healthy subjects, dulaglutide increased the mean insulin AUC0-10 by 3.09-fold and Cmax0-10 by 2.96-fold vs placebo, and mean AUC10-180 and Cmax10-180 by 2.04- and 4.15-fold, respectively.
    Summary · context
    In this randomized, double-blind, placebo-controlled, 2-period crossover study, subjects received a single subcutaneous injection of dulaglutide 1.5 mg or placebo on day 1 of each period.
  10. 10HumanRandomized controlled trialMechanism

    In the glucose challenge study, dulaglutide increased mean glucose disappearance constant versus placebo.

    In plain wordsDulaglutide increased the glucose disappearance constant versus placebo in the challenge study.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseGlucose disappearance constant
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Mean Kg and HOMA-β were higher after dulaglutide compared with placebo.
    1 context sentence
    Summary · context
    In this randomized, double-blind, placebo-controlled, 2-period crossover study, subjects received a single subcutaneous injection of dulaglutide 1.5 mg or placebo on day 1 of each period.
  11. 11HumanRandomized controlled trialMechanism

    In the glucose challenge study, dulaglutide increased mean HOMA-β versus placebo.

    In plain wordsDulaglutide increased an estimate of pancreatic beta-cell function versus placebo.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseHOMA-beta
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Mean Kg and HOMA-β were higher after dulaglutide compared with placebo.
    1 context sentence
    Summary · context
    In this randomized, double-blind, placebo-controlled, 2-period crossover study, subjects received a single subcutaneous injection of dulaglutide 1.5 mg or placebo on day 1 of each period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.